Amgen

AI-driven drug discovery and regulatory integration

23 clusters · 65 sources · last updated about 18 hours ago

Latest: AI-driven drug discovery platforms gain momentum with new funding and technology

By late 2026, the pharmaceutical industry has transitioned from pilot programs to full-scale execution, focusing on a ‘data closed loop’ through major partnerships such as Eli Lilly and NVIDIA, and Merck & Co., Inc. with

GLP-1 drugs: clinical trends, safety, and market shifts

327 clusters · 1186 sources · last updated 1 day ago

Latest: GLP-1 medication usage impacts nutrition trends and various business sectors

The clinical and economic landscape of GLP-1 medications continues to expand. Beyond obesity, research indicates potential benefits for psychiatric, respiratory, and neurodegenerative health. Recent findings suggest thes

Tezspire clinical trial results for EoE

2 clusters · 2 sources · last updated 2 days ago

Latest: Amgen and AstraZeneca report positive clinical trial results for specialized therapies

Clinical trial results from the phase III CROSSING study indicate that tezepelumab (Tezspire), developed by AstraZeneca and Amgen, shows significant improvement for adolescents and adults with symptomatic, uncontrolled e

OpenAI GPT-Rosalind life sciences model expansion

3 clusters · 7 sources · last updated 3 days ago

Latest: OpenAI restricts access to GPT-Rosalind-6 biology model

OpenAI has begun structuring its GPT-Rosalind series into a specialized product line for the life sciences sector. Following the introduction of pricing for the gpt-rosalind-discovery and gpt-rosalind-research models, th

Biotechnology sector quarterly earnings

2 clusters · 7 sources · last updated 4 days ago

Latest: Amgen reports 10% revenue growth in second quarter

The biotechnology sector reported varied quarterly financial results. Regeneron announced a 36% year-over-year revenue increase to $5.1 billion, driven by sales of Dupixent and EYLEA HD, alongside positive early clinical

ES-SCLC combination therapy clinical trial results

3 clusters · 23 sources · last updated 6 days ago

Latest: Dual immunotherapy improves survival for small cell lung cancer patients

Results from the Phase 3 DeLLphi-305 clinical trial indicate that a combination of Amgen’s Imdelltra (tarlatamab) and AstraZeneca’s Imfinzi (durvalumab) significantly improves survival outcomes for patients with extensiv

Advancements in metastatic cancer clinical trials

4 clusters · 25 sources · last updated 6 days ago

Latest: Sacituzumab tirumotecan improves survival in advanced endometrial cancer trial

Recent phase 3 clinical trials have demonstrated significant survival benefits for various metastatic cancer treatments. In gastroesophageal adenocarcinoma, the HERIZON-GEA-01 trial showed that zanidatamab combined with

Biotechnology sector expansion in Latin America

2 clusters · 2 sources · last updated 9 days ago

Latest: Biotechnology companies expand operations in Latin America

The biotechnology sector in Latin America is seeing significant activity, driven by both international corporations and regional firms. Amgen has selected Buenos Aires, Argentina, as the headquarters for a new regional c

Rising osteoporosis diagnoses and gender-specific risks

4 clusters · 33 sources · last updated 9 days ago

Latest: Osteoporosis awareness highlights risks of silent bone density loss

Medical specialists continue to report a rising trend in osteoporosis diagnoses among individuals under the age of 50. While traditionally associated with the elderly and postmenopausal women, experts at the Spanish Soci

Schwab U.S. Dividend Equity ETF performance and strategy

6 clusters · 12 sources · last updated 11 days ago

Latest: Schwab U.S. Dividend Equity ETF highlighted for passive income growth

Investors evaluating dividend-focused exchange-traded funds (ETFs) continue to weigh the Schwab U.S. Dividend Equity ETF (SCHD) against high-yield and growth-oriented alternatives. SCHD maintains a low-cost profile with

Tea consumption and cardiovascular disease study

2 clusters · 22 sources · last updated 11 days ago

Latest: Research highlights tea consumption and cardiac rehabilitation challenges

A long-term observational study involving nearly 500,000 adults in China has linked regular tea consumption to an 11% lower risk of developing vascular diseases, such as stroke and heart disease. Researchers from Peking

Advancements in Italian oncology and radiotherapy

4 clusters · 34 sources · last updated 29 days ago

Latest: Italy advances leukemia treatment through immunotherapy and integrated care models

Italian medical institutions continue to advance oncology through specialized training, genomic profiling, and personalized care models. To support genomic cancer profiling for approximately 15,000 eligible patients annu